X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html
https://endpts.com/fda-lifts-partial-hold-on-curis-phi-ii-leukemia-study-as-biotech-raises-15m/
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-on-takeaim-leukemia-trial-of-emavusertib-in-aml-mds
https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle
https://www.fiercebiotech.com/biotech/fda-sparks-hope-curis-lets-biotech-resume-enrollment-part-phase-12-leukemia-study
https://www.prnewswire.com/news-releases/curis-announces-encouraging-emavusertib-data-at-the-2022-american-society-of-clinical-oncology-annual-meeting-asco-301561339.html
Market Place
Share 
